BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND RANBP2, NUP358, 5903, ENSG00000153201, P49792, TRP1, TRP2
13 results:

  • 1. Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy.
    Baranov E; Winsnes K; O'Brien M; Voss SD; Church AJ; Janeway KA; DuBois SG; Davis JL; Al-Ibraheemi A
    Histopathology; 2022 Aug; 81(2):215-227. PubMed ID: 35543076
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. GILT in Thymic Epithelial Cells Facilitates Central CD4 T Cell Tolerance to a Tissue-Restricted, Melanoma-Associated Self-Antigen.
    Rausch MP; Meador LR; Metzger TC; Li H; Qiu S; Anderson MS; Hastings KT
    J Immunol; 2020 Jun; 204(11):2877-2886. PubMed ID: 32269095
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Dormant tumor cells interact with memory CD8
    Flores-Guzmán F; Utikal J; Umansky V
    Cancer Lett; 2020 Apr; 474():74-81. PubMed ID: 31962142
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Tumor-Specific Regulatory T Cells from the bone Marrow Orchestrate Antitumor Immunity in Breast cancer.
    Ge Y; Böhm HH; Rathinasamy A; Xydia M; Hu X; Pincha M; Umansky L; Breyer C; Hillier M; Bonertz A; Sevko A; Domschke C; Schuetz F; Frebel H; Dettling S; Herold-Mende C; Reissfelder C; Weitz J; Umansky V; Beckhove P
    Cancer Immunol Res; 2019 Dec; 7(12):1998-2012. PubMed ID: 31672785
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
    Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
    Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Could mucin 16 and colony-stimulating factor 2-receptor beta possible graft versus host disease biomarkers? Medical hypotheses.
    Souza MM; de Paula FM; Hsieh R; Macedo MC; Corral MA; Nunes TB; De Paula F; Lourenço SV
    Med Hypotheses; 2017 Mar; 100():89-93. PubMed ID: 28236856
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. ranbp2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia.
    Lim JH; Jang S; Park CJ; Cho YU; Lee JH; Lee KH; Lee JO; Shin JY; Kim JI; Huh J; Seo EJ
    Cancer Genet; 2014; 207(1-2):40-5. PubMed ID: 24613277
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Insoluble fraction of tumor cell homogenate is a useful material for eliciting cytotoxic T lymphocytes: a unique method for protein solubilization.
    Kuwada E; Kambara K; Tadaki T; Noguchi K
    Anticancer Res; 2011 Mar; 31(3):881-91. PubMed ID: 21498709
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. SAGE analysis highlights the importance of p53csv, ddx5, mapkapk2 and ranbp2 to multiple myeloma tumorigenesis.
    Felix RS; Colleoni GW; Caballero OL; Yamamoto M; Almeida MS; Andrade VC; Chauffaille Mde L; Silva WA; Begnami MD; Soares FA; Simpson AJ; Zago MA; Vettore AL
    Cancer Lett; 2009 Jun; 278(1):41-8. PubMed ID: 19171422
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Novel C5a agonist-based dendritic cell vaccine in a murine model of melanoma.
    Floreani AA; Gunselman SJ; Heires AJ; Hauke RJ; Tarantolo S; Jackson JD
    Cell Cycle; 2007 Nov; 6(22):2835-9. PubMed ID: 17986862
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Limitations of the immunocytochemical detection of isolated tumor cells in frozen samples of bone marrow obtained from melanoma patients.
    Schadendorf D; Dorn-Beineke A; Borelli S; Riethmuller G; Pantel K
    Exp Dermatol; 2003 Apr; 12(2):165-71. PubMed ID: 12702145
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Dendritic cells break tolerance and induce protective immunity against a melanocyte differentiation antigen in an autologous melanoma model.
    Schreurs MW; Eggert AA; de Boer AJ; Vissers JL; van Hall T; Offringa R; Figdor CG; Adema GJ
    Cancer Res; 2000 Dec; 60(24):6995-7001. PubMed ID: 11156402
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.
    Zhang W; He L; Yuan Z; Xie Z; Wang J; Hamada H; Cao X
    Hum Gene Ther; 1999 May; 10(7):1151-61. PubMed ID: 10340547
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.